Company intelligence / Profile preview
ViaDerma, Inc.
- Ownership
- Private
- Employees
- ~25
- Development stage
- Commercial
Overview
ViaDerma's lead product Vitastem is an FDA-registered topical antibiotic that utilizes an innovative transdermal delivery method. It has undergone over 10 years of clinical testing and is reported to kill all harmful bacteria available for testing, delivering results within 24 hours compared to 5-7 days for other products[1][2].
- Therapeutic areas
- Men's HealthOncologyEndocrinologyOtherDermatologyNeurologyInfectious Diseases
- Modalities
- Topical antibioticsTransdermal delivery systems
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on ViaDerma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViaDerma, Inc..